These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 31262908

  • 1. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
    Gerogianni I, Pitaraki E, Jagirdar RM, Kouliou O, Giannakou L, Giannopoulos S, Papazoglou E, Hatzoglou C, Gourgoulianis KI, Zarogiannis SG.
    Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.
    Laszlo V, Valko Z, Ozsvar J, Kovacs I, Garay T, Hoda MA, Klikovits T, Stockhammer P, Aigner C, Gröger M, Klepetko W, Berger W, Grusch M, Tovari J, Waizenegger IC, Dome B, Hegedus B.
    J Mol Med (Berl); 2019 Feb; 97(2):231-242. PubMed ID: 30539198
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E, Pandolfi L, Colombo M, Frangipane V, Inghilleri S, Morosini M, Mrakic-Sposta S, Moretti S, Monti M, Pignochino Y, Benvenuti S, Prosperi D, Stella G, Morbini P, Meloni F.
    Int J Nanomedicine; 2019 Feb; 14():773-785. PubMed ID: 30774332
    [Abstract] [Full Text] [Related]

  • 6. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I, Colangelo D, Osella D.
    Curr Cancer Drug Targets; 2018 Feb; 18(8):816-828. PubMed ID: 28669341
    [Abstract] [Full Text] [Related]

  • 7. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
    Onen HI, Yilmaz A, Alp E, Celik A, Demiroz SM, Konac E, Kurul IC, Menevse ES.
    Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
    [Abstract] [Full Text] [Related]

  • 8. Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment.
    Karatkevich D, Losmanova T, Zens P, Deng H, Dubey C, Zhang T, Casty C, Gao Y, Neppl C, Berezowska S, Wang W, Peng RW, Schmid RA, Dorn P, Marti TM.
    Sci Rep; 2024 Aug 06; 14(1):18206. PubMed ID: 39107509
    [Abstract] [Full Text] [Related]

  • 9. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
    Karatkevich D, Deng H, Gao Y, Flint E, Peng RW, Schmid RA, Dorn P, Marti TM.
    Int J Mol Sci; 2022 Oct 08; 23(19):. PubMed ID: 36233258
    [Abstract] [Full Text] [Related]

  • 10. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.
    Mol Cancer Ther; 2016 Oct 08; 15(10):2357-2369. PubMed ID: 27512118
    [Abstract] [Full Text] [Related]

  • 11. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K.
    J Clin Oncol; 2019 Oct 01; 37(28):2537-2547. PubMed ID: 31386610
    [Abstract] [Full Text] [Related]

  • 12. Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.
    Sonvico F, Barbieri S, Colombo P, Barocelli E, Mucchino C, Cantoni AM, Petronini PG, Rusca M, Carbognani P, Ampollini L.
    Eur J Pharm Sci; 2018 Oct 15; 123():89-97. PubMed ID: 30030099
    [Abstract] [Full Text] [Related]

  • 13. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T, Gesmundo I, Audrito V, Vitale N, Silvagno F, Musuraca C, Righi L, Libener R, Riganti C, Bironzo P, Deaglio S, Papotti M, Cai R, Sha W, Ghigo E, Schally AV, Granata R.
    Proc Natl Acad Sci U S A; 2019 Feb 05; 116(6):2226-2231. PubMed ID: 30659154
    [Abstract] [Full Text] [Related]

  • 14. EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma.
    Yang L, Fang H, Jiang J, Sha Y, Zhong Z, Meng F.
    Drug Deliv Transl Res; 2022 Oct 05; 12(10):2527-2536. PubMed ID: 34802094
    [Abstract] [Full Text] [Related]

  • 15. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T, Itano H, Fukita S, Saitoh M, Takeda S.
    Intern Med; 2014 Oct 05; 53(20):2347-51. PubMed ID: 25318801
    [Abstract] [Full Text] [Related]

  • 16. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T.
    Gan To Kagaku Ryoho; 2017 Dec 05; 44(13):2041-2047. PubMed ID: 29361614
    [Abstract] [Full Text] [Related]

  • 17. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
    Maehara S, Usuda J, Ishizumi T, Ichinose S, Ohtani K, Inoue T, Imai K, Furumoto H, Kudo Y, Kajiwara N, Ohira T, Ikeda N.
    Int J Oncol; 2015 Feb 05; 46(2):741-9. PubMed ID: 25385189
    [Abstract] [Full Text] [Related]

  • 18. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.
    Cancer Chemother Pharmacol; 2008 Apr 05; 61(4):549-58. PubMed ID: 17522864
    [Abstract] [Full Text] [Related]

  • 19. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT).
    Lancet; 2016 Apr 02; 387(10026):1405-1414. PubMed ID: 26719230
    [Abstract] [Full Text] [Related]

  • 20. Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma.
    Satoh T, Tatsuta T, Sugawara S, Hara A, Hosono M.
    Oncotarget; 2017 Jun 27; 8(26):42466-42477. PubMed ID: 28476017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.